Blavatnik Biomedical Accelerator


A Proven Track Record of Success in Biomedical Research Commercialization

The original Harvard Biomedical Accelerator was launched in 2007 and expanded in 2013 as the Blavatnik Biomedical Accelerator at Harvard University, through the generosity of a major gift from the Blavatnik Family Foundation.

To date, it has provided $18.5 million in direct research support to 104 projects from across the University. Funded technologies have included therapeutics (oncology, metabolic disease, diabetes, immuno-inflammatory disease, infectious diseases, and neurodegeneration), diagnostics/biomarkers, instruments, and other biomedical technologies. Almost half of all completed projects have been partnered with industry through licensing transactions with existing pharmaceutical and biotech companies, through the formation of new startups, or through the establishment of new research collaborations. These alliances have already led to more than $40 million in industry-sponsored research funding in the near-term, and they have the potential to generate significant milestone and royalty income in the future.

We are committed to continuing that record of success through targeted translational research funding and support. The following success stories illustrate the compelling track record of the Blavatnik Biomedical Accelerator.

Blood Diseases and Immune Disorders

With support from the Blavatnik Biomedical Accelerator over two years, Professor David Scadden developed a milder method to carry out the bone marrow conditioning necessary in advance of hematopoetic stem cell transplantation.

Result: We completed a license agreement with Magenta Therapeutics, a startup company launched in Cambridge with a $48.5M Series A. The licensed portfolio of technologies has the potential to transform blood stem cell transplants from a “treatment of last resort” into a safer, more efficient therapy for patients with blood diseases and immune disorders.

Read More

David Scadden

Cancer Therapeutics

Professor Matthew Shair discovered a novel therapeutic strategy for the treatment of AML—namely, to inhibit enzymes that regulate the transcription of key genetic programs that are altered in AML and other cancers. With accelerator support, Shair’s laboratory has developed highly selective and potent small molecules, with favorable pharmaceutical properties, poised for advancement toward clinical trials.

Result: We executed a license agreement with Merck; the company also engaged in a research collaboration with the Shair laboratory to further investigate the biology of transcriptional regulator enzymes.

Read More

Antibiotic Platform Company

Professor Andy Myers developed a novel platform for antibiotic synthesis and, with accelerator funding, demonstrated total synthesis of a major class of antibiotics called macrolides, including a number of promising new structures.

Result: A startup, Macrolide Pharmaceuticals (now Zikani Therapeutics) launched out of the Myers lab and raised $22M in Series A financing. The company is developing novel antibiotics for the treatment of serious gram-positive and gram-negative bacterial infections.

Read More

Anti-fibrotic Drug with Origins in Traditional Chinese Medicine

Professor Malcolm Whitman led a project investigating the anti-inflammatory and anti-fibrotic effects of halofuginone, a derivative of a compound found in blue evergreen hydrangea. With accelerator funding, he designed chemical modifications to halofuginone to reduce its side effects and identified the treatment of fibrotic diseases, including idiopathic pulmonary fibrosis, as a promising application.

Result: We launched a startup with Allied Bristol Life Sciences, a new enterprise formed by Allied Minds and Bristol-Myers Squibb specifically to advance biomedical innovations from leading academic research institutions.

Read More

Rotational Spectroscopy Instrument

Accelerator funding enabled Professor John Doyle to develop a biomedical instrument technology with pharmaceutical applications.

Result: The technology was licensed to BrightSpec, a company that produces rotational spectroscopy instrumentation that is used for molecular structure determination.

Increasing Degradation of Toxic Proteins to Treat Neuro-degenerative Diseases and Cancer

Through their research, professors Dan Finley and Randy King investigated the role of key enzymes in the cellular system for degrading proteins. Their hypothesis: that amplifying this system to remove accumulated toxic proteins that cause cell dysfunction and death could provide new avenues for treatment of Alzheimer’s disease, Parkinson’s disease, and cancer. 

Result: Following 18 months of Accelerator-funded support and collaboration, the resulting technology was licensed to Proteostasis Therapeutics.

Read More

The drug development experience at the heart of the program provides advice that can be hard or impossible for academics to get otherwise; even those that have been around the block.

Dan Finley, PhD

Department of Cell Biology
Harvard Medical School

Improving Biomedically Important Molecules Using Fluorine

A major goal for pharmaceutical chemistry has been to develop effective methods to incorporate fluorine atoms into complex molecules. Professor Tobias Ritter’s research focuses on realizing the numerous benefits fluorine can impart to drugs, including greater absorption from the intestine, increased stability in the body, and greater effectiveness at therapeutic protein targets. 

Result: Accelerator funding helped Professor Ritter develop novel techniques and chemical reagents to achieve this goal, leading to the formation of SciFluor Life Sciences. The technology has potential for wide-ranging applications in multiple areas of pharmaceutical science and medicine, including novel therapeutics and imaging agents for disease diagnosis.